Article
The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy
Registro en:
CARNEIRO NETO, J. A. et al. The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy. Revista da Sociedade Brasileira de Medicina Tropical, v. 47, n. 4, p. 528-532, 2014.
0037-8682
Autor
Carneiro Neto, José Abraão
Bittencourt, Valéria Gusmão
Oliveira, Cassius de
Andrade, Rosana
Carvalho Filho, Edgar Marcelino
Resumen
CARVALHO FILHO, Edgar Marcelino de. “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”. Brazilian National Research Council CNPq - (Conselho Nacional de Desenvolvimento Científico e Tecnológico Urinary symptoms occur in 19% of human T-cell lymphotropic virus type 1 (HTLV-1)-infected patients who do not fulfi ll criteria
for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and in almost 100% of HAM/TSP patients. Few
studies have evaluated therapies for overactive bladder (OAB) caused by HTLV-1 infection. This case report describes the effect
of onabotulinum toxin A on the urinary manifestations of three patients with HAM/TSP and OAB symptoms. The patients were
intravesically administered 200 units of Botox®. Their incontinence episodes improved, and their OAB symptoms scores (OABSS)
reduced signifi cantly. These data indicate that Botox® should be a treatment option for OAB associated with HTLV-1 infection